First Bank & Trust trimmed its holdings in shares of AstraZeneca plc (NYSE:AZN) by 90.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,911 shares of the company’s stock after selling 18,829 shares during the quarter. First Bank & Trust’s holdings in AstraZeneca were worth $77,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Lake Point Wealth Management purchased a new position in AstraZeneca during the 4th quarter valued at about $195,000. Mackenzie Financial Corp boosted its holdings in AstraZeneca by 311.8% during the 4th quarter. Mackenzie Financial Corp now owns 122,231 shares of the company’s stock valued at $4,642,000 after acquiring an additional 92,551 shares during the period. Sit Investment Associates Inc. purchased a new position in shares of AstraZeneca in the 4th quarter valued at about $171,000. Wealth Alliance Advisory Group LLC purchased a new position in shares of AstraZeneca in the 4th quarter valued at about $216,000. Finally, Cavalier Investments LLC purchased a new position in shares of AstraZeneca in the 4th quarter valued at about $889,000. 18.31% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE AZN opened at $39.30 on Wednesday. The company has a current ratio of 0.96, a quick ratio of 0.78 and a debt-to-equity ratio of 1.24. AstraZeneca plc has a fifty-two week low of $34.38 and a fifty-two week high of $43.29. The stock has a market cap of $100.83 billion, a PE ratio of 11.36, a price-to-earnings-growth ratio of 1.16 and a beta of 0.51.
AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, February 14th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.85. AstraZeneca had a return on equity of 32.47% and a net margin of 9.76%. The business had revenue of $6.42 billion for the quarter, compared to analyst estimates of $6.33 billion. During the same quarter last year, the company earned $1.30 EPS. The business’s quarterly revenue was up 11.1% on a year-over-year basis. Equities analysts forecast that AstraZeneca plc will post 1.79 EPS for the current year.
The firm also recently announced a semiannual dividend, which was paid on Wednesday, March 27th. Stockholders of record on Friday, March 1st were given a dividend of $0.95 per share. This represents a dividend yield of 4.64%. The ex-dividend date of this dividend was Thursday, February 28th. This is a positive change from AstraZeneca’s previous semiannual dividend of $0.45. AstraZeneca’s dividend payout ratio (DPR) is 53.76%.
Several equities analysts have recently issued reports on AZN shares. Deutsche Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, February 26th. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Main First Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, March 19th. BMO Capital Markets reiterated a “buy” rating and issued a $48.00 price objective on shares of AstraZeneca in a research note on Tuesday, January 15th. Finally, Zacks Investment Research upgraded AstraZeneca from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Thursday, April 4th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $45.29.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.